{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T19:25:13Z","timestamp":1763580313420},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T00:00:00Z","timestamp":1456358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bjid.2016.02.002","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:56:10Z","timestamp":1457484970000},"page":"401-402","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long term effect of switching to darunavir\/ritonavir in HIV infected patients previously on protease inhibitor therapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Claudio","family":"Ucciferri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Falasca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Vignale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Vecchiet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2016.02.002_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh013","article-title":"Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients","volume":"53","author":"Calza","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2016.02.002_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct1001-1","article-title":"Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels","volume":"10","author":"Hill","year":"2009","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.bjid.2016.02.002_bib0040","first-page":"566","article-title":"Factors associated with an atherogenic lipid profile in premenopausal women without clinical cardiovascular disease","volume":"110","author":"Guerrero Igea","year":"1998","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.bjid.2016.02.002_bib0045","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/jmv.23543","article-title":"Improved metabolic profile after switch to darunavir\/ritonavir in HIV positive patients previously on protease inhibitor therapy","volume":"85","author":"Ucciferri","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.bjid.2016.02.002_bib0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2174\/157016210791330365","article-title":"Cystatin C, adipokines and cardiovascular risk in HIV infected patients","volume":"8","author":"Falasca","year":"2010","journal-title":"Curr HIV Res"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867016300320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867016300320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T13:28:09Z","timestamp":1536931689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867016300320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1413867016300320"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2016.02.002","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long term effect of switching to darunavir\/ritonavir in HIV infected patients previously on protease inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2016.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}